NEXGEL (NXGL) investor relations material

Strategic acquisition and partnership

• Acquired Celularity's biomaterials and wound care divisions, previously Celularity's main revenue drivers.

• Established BIONX Surgical as a wholly owned subsidiary to market acquired products.

• Formed a strategic partnership with Fountainhead Life Sciences, providing product flow, backup manufacturing, and a $6.5 million investment.

• Fountainhead brings 35 cleared 510(k)s, 21 patents, and a vertically integrated system including manufacturing and education.

• BIONX now serves as the market-facing gateway for all Fountainhead products, curating a closed-loop experience for practitioners.

Product portfolio and pipeline expansion

• Expanded product lineup to offer a full suite of regenerative medicine solutions, including six acquired products and three 510(k) pipeline products.

• Key products include BIOVANCE, Interfyl, Sentry, SilverSeal, ActivAide, Forma, and upcoming ocular products launching August 1.

• Sentry targets the lower-cost wound care segment, while BIOVANCE is positioned as a premium, decellularized matrix product.

• SilverSeal, now with reimbursement codes, is positioned as an alternative in wound care due to new reimbursement rules.

• ORCHID, a new injectable product using the entire placenta, will replace Interfyl and expand into aesthetics.

Commercial strategy and sales force development

• Direct sales force established, ending reliance on third-party partners and improving margins.

• Products are approved in 500 hospitals nationwide, with a unified BIONX brand experience.

• Reengaged 65 sales reps across 13 organizations, aiming for 200-300 by year-end.

• Cadaver Lab education programs launching mid-July to engage practitioners and gather product feedback.

• Commercialization plan includes leveraging KOLs, early evidence, and scaling through shared services with Fountainhead.